Cohance Lifesciences Ltd (COHANCE) is currently trading at 425.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Cohance Lifesciences is an integrated CDMO providing custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs, formulated drugs, ADC payloads and oligonucleotide building blocks for global pharma, biotech and specialty-chemical innovators, with manufacturing and R&D facilities across India and a presence in New Jersey supporting advanced modalities. The company is in a transition phase with FY26 impacted by customer-led de-stocking and timing shifts, leading to an early-to-mid double-digit revenue decline guidance while management expects recovery and return to growth in FY27 as Phase III and commercial programmes convert for Cohance Lifesciences. Advanced modality investments remain strategic: Cohance is the exclusive ADC payload intermediate supplier to a major innovator, has filed new ADC DMFs, and is commissioning a USD 10m US cGMP expansion to support Phase 2b supply, underscoring continued focus on high-value, differentiated technology platforms. Operationally Cohance generated free cash flow and retained net cash of INR 1.76 billion in 9MFY26 despite capex of INR 1.61 billion towards oligo and capacity expansion, demonstrating resilient cash generation while absorbing integration and remediation costs. Quality and governance actions are central: the company embedded senior quality leadership, engaged external advisors after an OAI→Warning Letter event at Nacharam FDF, and reports OTIF above 95%, positioning quality remediation and regulatory engagement as enablers for future scale at Cohance Lifesciences.

Over the past 52 weeks, Cohance Lifesciences Ltd has traded between a low of ₹267.85 and a high of ₹1,006.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Cohance Lifesciences Ltd has a market capitalization of approximately 16,834.28. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Cohance Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 287.62 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 16,834.28 Cr, Cohance Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Cohance Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Cohance Lifesciences Ltd is 287.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Cohance Lifesciences Limited is the new identity of erstwhile Suven Pharmaceuticals Limited.

It announced US$10 million for a cGMP bioconjugation suite at NJ Bio (Princeton, US) and ₹230 million (₹23 crore) for a cGMP oligonucleotide building block facility in Hyderabad.

Biopharma Shakti is a new initiative with a ₹10,000 crore outlay over five years aimed at making India a global hub for biopharma manufacturing, focusing on biologics and biosimilars.